Taken together, we speculated that NFE2L3, a novel biomarker in malignant pleural mesothelioma, can promote Th2 cell differentiation via IL-2/STAT5/NLRP3 signaling pathway in mesothelioma and many other cancers. This evidence concerns the gene IL2 and malignant pleural mesothelioma.